Literature DB >> 21734581

Radiation for bone metastases.

Daniel J Bourgeois1, Stephen Kraus, Bassam N Maaloof, Oliver Sartor.   

Abstract

PURPOSE OF REVIEW: To synopsize the current state-of-the-art for radiation and treatment of painful bone metastases with a focus on prostate cancer. RECENT
FINDINGS: Although external beam radiation has long been known to palliate painful bone metastatic disease for patients with prostate cancer, new studies continue to evolve in this area. Data from randomized studies over the past decade emphasize that palliation can be achieved with single-fraction radiation strategies. Despite these data, and various supportive national and international guidelines, single-fraction regimens are relatively underutilized in the USA as compared with other countries. In addition to external beam radiation, beta-emitting isotopes are also effective as systemic agents for the palliation of painful bone metastases. New alpha-emitters such as Alpharadin (radium-223) are under current development but remain unproven at this time and recent data indicate that this agent can prolong survival in patients with advanced prostate cancer.
SUMMARY: Radiation in various forms is highly effective for palliation of pain associated with bone metastases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734581     DOI: 10.1097/SPC.0b013e3283499caa

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  3 in total

1.  Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone.

Authors:  Eleonora Dondossola; Stefano Casarin; Claudia Paindelli; Elena M De-Juan-Pardo; Dietmar W Hutmacher; Christopher J Logothetis; Peter Friedl
Journal:  J Natl Cancer Inst       Date:  2019-10-01       Impact factor: 13.506

Review 2.  Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.

Authors:  Jatinder Goyal; Emmanuel S Antonarakis
Journal:  Cancer Lett       Date:  2012-04-17       Impact factor: 8.679

Review 3.  Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature.

Authors:  Jan Norum; Erik R Traasdahl; Arpad Totth; Carsten Nieder; Jan Abel Olsen
Journal:  Glob J Health Sci       Date:  2015-07-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.